Evolus (EOLS) Competitors $6.40 +0.10 (+1.59%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.35 -0.05 (-0.78%) As of 10/17/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. RCUS, HRMY, AUPH, PAHC, SDGR, HROW, SNDX, EVO, ZYME, and AVDLShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), Phibro Animal Health (PAHC), Schrodinger (SDGR), Harrow (HROW), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Zymeworks (ZYME), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Arcus Biosciences Harmony Biosciences Aurinia Pharmaceuticals Phibro Animal Health Schrodinger Harrow Syndax Pharmaceuticals Evotec Zymeworks Avadel Pharmaceuticals Evolus (NASDAQ:EOLS) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Which has higher valuation and earnings, EOLS or RCUS? Evolus has higher revenue and earnings than Arcus Biosciences. Evolus is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M1.55-$50.42M-$0.98-6.53Arcus Biosciences$258M6.80-$283M-$3.17-5.20 Does the media favor EOLS or RCUS? In the previous week, Arcus Biosciences had 8 more articles in the media than Evolus. MarketBeat recorded 10 mentions for Arcus Biosciences and 2 mentions for Evolus. Evolus' average media sentiment score of 0.43 beat Arcus Biosciences' score of -0.08 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Which has more risk and volatility, EOLS or RCUS? Evolus has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Is EOLS or RCUS more profitable? Evolus has a net margin of -22.31% compared to Arcus Biosciences' net margin of -109.56%. Arcus Biosciences' return on equity of -55.96% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.31% -759.04% -24.63% Arcus Biosciences -109.56%-55.96%-25.73% Do insiders and institutionals have more ownership in EOLS or RCUS? 90.7% of Evolus shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate EOLS or RCUS? Evolus presently has a consensus target price of $21.25, suggesting a potential upside of 232.03%. Arcus Biosciences has a consensus target price of $26.78, suggesting a potential upside of 62.39%. Given Evolus' higher possible upside, analysts clearly believe Evolus is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Arcus Biosciences 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryEvolus and Arcus Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$407.52M$10.71B$6.10B$10.50BDividend YieldN/A1.88%5.73%4.81%P/E Ratio-6.5319.6784.5227.09Price / Sales1.5531.17586.66210.72Price / CashN/A25.0337.1661.22Price / Book71.113.4112.246.52Net Income-$50.42M$210.63M$3.32B$276.75M7 Day Performance4.23%0.03%1.25%2.00%1 Month Performance-0.31%-1.38%6.28%2.26%1 Year Performance-61.49%-9.70%59.92%35.58% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.9389 of 5 stars$6.40+1.6%$21.25+232.0%-61.5%$407.52M$266.27M-6.53170Analyst ForecastRCUSArcus Biosciences2.3868 of 5 stars$16.64+14.0%$23.38+40.5%-9.6%$1.55B$258M-5.25500Gap UpHRMYHarmony Biosciences4.7598 of 5 stars$26.36-0.7%$46.11+74.9%-25.9%$1.53B$714.73M8.50200Analyst ForecastAUPHAurinia Pharmaceuticals2.8876 of 5 stars$11.10-1.5%$13.00+17.1%+60.9%$1.48B$235.13M25.81300PAHCPhibro Animal Health4.0633 of 5 stars$36.58+0.5%$28.40-22.4%+63.1%$1.48B$1.30B31.002,475Analyst ForecastSDGRSchrodinger3.4427 of 5 stars$19.70+3.2%$26.29+33.4%+9.8%$1.40B$207.54M-7.94790Analyst ForecastHROWHarrow2.9417 of 5 stars$38.77+3.4%$68.50+76.7%-29.1%$1.39B$199.61M-155.08180SNDXSyndax Pharmaceuticals3.987 of 5 stars$15.20-5.4%$39.22+158.0%-28.1%$1.38B$23.68M-3.91110News CoverageAnalyst UpgradeEVOEvotec1.6617 of 5 stars$3.95+2.1%$7.00+77.2%+26.0%$1.37B$862.40M0.004,827News CoverageGap DownZYMEZymeworks2.7597 of 5 stars$18.11+0.3%$22.50+24.2%+36.6%$1.36B$122.87M-12.07460Trending NewsAnalyst ForecastAnalyst RevisionAVDLAvadel Pharmaceuticals2.5985 of 5 stars$14.20+1.4%$20.86+46.9%+9.3%$1.36B$169.12M-473.3370 Related Companies and Tools Related Companies Arcus Biosciences Competitors Harmony Biosciences Competitors Aurinia Pharmaceuticals Competitors Phibro Animal Health Competitors Schrodinger Competitors Harrow Competitors Syndax Pharmaceuticals Competitors Evotec Competitors Zymeworks Competitors Avadel Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
